NCT00092924View on ClinicalTrials.gov

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Primary Completion Date

January 31, 2005

Study Completion Date

March 31, 2005

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

TRAIL-R1 mAb (TRM-1;HGS-ETR1)

Trial Locations (5)

27710

Duke Comprehensive Cancer Center, Durham

37203

Sarah Cannon Cancer Center, Nashville

60612

Rush Medical College, Chicago

77230

MD Anderson, Houston

80220

University of Colorado Cancer Center, Denver

Sponsors
All Listed Sponsors
lead

Human Genome Sciences Inc.

INDUSTRY

NCT00092924 - Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter